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Using the uninvolved and involved skin from psoriatic 
patients, we investigated the effects of histamine and 
AMP (or adenosine) in vitro on the intracellular cyclic 
AMP levels. Both agents activated adenylate cyclase of 
the uninvolved and involved resulting in the accumula-
tion of cyclic AMP. Without a cyclic nucleotide phospho-
diesterase (PDE) inhibitor, these responses were hi-
phasic and the maximal accumulation was observed in 
5 min. With the PDE inhibitor both responses were 
markedly potentiated and high levels of cyclic AMP were 
observed for more than 20 min. 
The response to histamine by the involved skin was 
much greater than that by the uninvolved. The degree of 
the response to adenosine was approximately equal. In 
accordance with our previous work, the response to 
epinephrine by the involved skin was much less than 
that by the uninvolved. Thus adenylate cyclases of in-
volved skin from psoriatic patients exhibit a markedly 
dimini~hed response to epinephrine while at the same 
time exhibiting a markedly enhanced response to hista-
mine. This precludes the possibility that the· unrespon-
siveness to epinephrine can be due to a generalized 
inability of the epidermal psoriatic plaque cell to make 
a functioning cell membrane. 
It has been suggested that altered cyclic nucleotide levels 
might be involved in the pathogenesis of psoriasis [1-4]. Voor-
hees et al [2] reported decreased cyclic AMP leve~s in psoriatic 
epidermis, however, this was not confirmed by Hiirkonen, 
Hopsu-Hava, and Raij [5], or by our data using the microdis-
sected pure epidermis [6,7]. The significance of changes in 
endogenous cyclic nucleotide levels, or an altered cyclic 
AMP/cyclic GMP ratio [3] in psoriasis remains unclear at this 
point. 
It also has been suggested that the receptor specific adenylate 
cyclase system might be defective in psoriatic epidermis, i.e., 
the accumulation of cyclic AMP after in vitro stimulation with 
epinephrine and other ,8-adrenergic agonists [8-10] and pros-
taglandin E (PGE) [11,12] was shown to be lower in the involved 
lesion than in the uninvolved skin of psoriasis patients. 
Elsewhere we have discussed the fact that whatever the 
findings may be in regard to cyclic nucleotide levels in an 
established lesion of psoriasis, such data on the levels alone 
does not shed any light on the changes which might have 
occurred at the onset of the lesion. At present this area is still 
completely unknown [13]. 
Previous data from our laboratory have shown that in addi-
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tion to epinephrine [14] and PGE [11] receptors, pig epidermal 
adenylate cyclase has 2 other independent receptors, histamine 
H2 [15,16] and adenosine and adenine nucleotides [17,18]. Con-
sequently in this study we investigated the response of psoriatic 
epidermis to these 2 other stimulators of adenylate cyclase and 
compared the responses in the uninvolved and involved skin 
for each stimulator. 
MATERIALS AND METHODS 
Epidermal samples were obtained from 8 adult male patients with 
well-developed psoriatic lesions. No active treatment was given for at 
least 7 days before taking the skin. In 1 patient (case 4) who had a 
concomitant asthma attack, epinephrine inhalation was given until 30 
min before taking the skin. No patient had systemic antihistamine for 
at least a week. Skin was taken from the back except for 2 cases (case 
1 and case 2 from the forearm) with a Castroviejo keratome. 
In most cases (cases 1, 2, 3, 4, 7, 8) sheets of skin were taken in 1 
piece going from uninvolved skin into the involved area with the 
keratome set to cut at 0.3 mm. This depth of slice is below the epidermis 
in the normal appearing area, but sometimes does cut off the bottom of 
the epidermal ridges in the involved area. In cases 5 and 6 the involved 
area was cut separately with the keratome set at 0.5 mm to obtain 
below the epidermal ridges. Neither systemic nor local anesthesia was 
given to avoid the possible effect on cyclic AMP level of skin. The 
removed skin was kept in Hank's balanced salt solution at 4 oc and 
used within 1 hr. Incubation was done as described previously [14,15] 
after preincubation for 15 to 20 min at 37°C [19]. Cyclic AMP levels in 
the epidermis were measured by Gilman's protein binding method [20] 
with slight modification [19]. Cyclic AMP levels in the incubation 
media were measured by the same binding assay after chromatographic 
purification. Namely, the media in which skin tissues had been incu-
bated were applied to Dowex AG 1 X 8 formate columns and the cyclic 
AMP fractions were eluted by 2 N formic acid. The eluates were freeze-
dried, reconstituted with small amounts of water, further purified with 
ZnS04-Ba(OH)2 precipitation, and finally subjected for the protein 
binding assay. Protein was measured by the method of Lowry, et a! 
[21]. 
Chemicals and drugs were all prepared fresh before each experiment 
and the pH of the media was adjusted to 7. Epinephrine was the 
product of Parke Davis (Detroit, Michigan) . All of the other chemicals 
were purchased from Sigma Chemical Company (St. Louis, Missouri) . 
RESULTS 
Figure 1 shows that the addition of histamine increased the 
cyclic AMP level in both uninvolved and involved epidermis, 
but the cyclic AMP level was much higher in the involved 
epidermis. The responses were short lived and the peak was 
observed in about 5 min. The addition ofthe phosphodiesterase 
inhibitor (theophylline) markedly potentiated the effect of his-
tamine in both uninvolved and involved epidermis, and even at 
20 min after the addition of histamine and theophylline, the 
cyclic AMP level was still high. With the addition of both 
agents the level of cyclic AMP was also higher in the involved 
epidermis. A time course study of histamine activation was 
repeated with skin from case 3 (0.3 mm depth for both unin-
volved and involved skin). Although the maximal accumulation 
of cyclic AMP was much less than that in case 5 (Fig 1) , the 
peak again was reached in 5 min and followed by decline. 
250 
Figure 2 is the effect of AMP in the uninvolved and involved 
epidermis. Since theophylline is a competitive inhibitor for the 
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FIG l. Time course of the effect of histamine in the uninvolved (0.3 
mm depth) and involved (0.5 mm depth) epidermis (case 5) . 6 = 
Uninvolved, histamine (1 mM); A = uninvolved, histamine (l mM) + 
theophylline (5 mM); 0 =involved, histamine (l mM); and e =involved, 
histamine (1 mM) + theophylline (5 mM). 
adenosine and adenine nucleotides receptor [17], papaverine 
was used as the phosphodiesterase inhibitor in this case. Essen-
tially the same pattern of cyclic AMP accumulation was ob-
served after AMP stimulation as was seen after histamine 
stimulation except for the fact that the difference between 
involved and uninvolved skin was much less marked. The 
phosphodiesterase inhibitor also potentiated the effect of AMP 
in both uninvolved and involved epidermis, and after stimula-
tion no difference was seen between involved and uninvolved 
skin. 
Table I shows the effects of histamine and AMP at different 
concentrations with the PDE inhibitor. The cyclic AMP accu-
mulation appeared to be dependent on the concentration of 
histamine added with the saturation concentration being be-
tween 100 JlM and 1 mM. The data suggests that 1 mM of AMP 
was sufficient to cause the maximal accumulation of cyclic 
AMP, our previous study with pig skin had also shown the 
maximal stimulation of AMP at 1 mM [17]. Either PDE inhib-
itor alone gave minimal effect on the cyclic AMP level. Because 
of numbers of observation points were not sufficient, the ap-
parent Km values were not calculated. Apparently the re-
sponses to variable substrate levels of histamine and AMP are 
approximately the sam e between the uninvolved and involved 
epidermis: hence the Km values may be assumed to be similar 
between the uninvolved and involved skin. 
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Table II shows the effects of histamine, AMP (or adenosine) 
and epinephrine on the cyclic AMP levels in the uninvolved 
and involved epidermis. Although the responses to 3 stimulators 
were markedly variable from case to case, the uninvolved skin 
100 
c: 
Q) 
-0 
.... 
Q. 
C) 
E 
Ill 
Q) 
0 
E 
Q. 50 
u 
u 
> 
u 
0 5 10 20 
minutes 
FIG 2. Time course of the effect of AMP in the uninvolved (0.3 mm 
depth) and involved (0.5 mm depth) epidermis (case 5). 6 = Unin-
volved, AMP (1 mM); A= uninvolved, AMP (1 mM) +papaverine (100 
J.LM); 0 = involved, AMP (1 mM); and e = involved, AMP (1 mM) + 
papaverine (100 J.LM). 
TABLE I. Effect of histamine (A) and AMP (B) concentrations 
A. Incubation was done for 7 min with various concentrations of 
histamine+ 5 mM theophylline. Skin was taken from case 6 (uninvolved 
0.3 mm depth, involved 0.5 mm depth). 
Cyclic AMP (pmoles/ mg protein) 
No Addition 
1 J.LM Histamine 
10 J.LM 
100 J.LM 
1 mM 
Uninvolved 
2.2 
3.5 
5.0 
8.4 
9.0 
Involved 
3.1 
3.5 
4.5 
9.0 
10.7 
B. Incubation was done for 7 min with various concentrations of 
AMP and 100 J.LM papaverine. Skin was taken from case 8 (uninvolved 
0.4 mrn depth, involved 0.4 mm depth). ND = not determined. 
Cyclic AMP (pmoles/ mg protein) 
No Addition 
1 J.LM 
10 J.LM 
100 J.LM 
500 J.LM 
1 mM 
Uninvolved 
1.1 
ND 
3.6 
14.6 
ND 
22.1 
Involved 
0.7 
3.9 
5.8 
9.3 
16.0 
19.2 
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TABLE II. Effects of histamine, AMP and epinephrine on the epidermal cyclic AMP accumulation . 
After the pre-incubation (15-20 min), the skin from uninvolved (U) and involved (I) were incubated with 3 stimulators for 7 min. Data are 
expressed as cyclic AMP pmoles/ mg protein. Concentrations of the drugs added to the media were: Histamine = 1 mM, Adenosine or AMP = 1 
mM, Epinephrine= 50 l-IM· Theophylline (5 mM) was added to the media .for the histamine a nd epinephrine experiments, papaverine (100 l-IM) was 
added for the AMP (adenosine) experiment. 00 = 0 time immediately after the pre-incubation. Control = 7 min late r with no additions. 
Case 1 2 3 4" 5 6 7 8 
Biopsy site Forearm Forearm Back Back Back Back Back Back flank 
u I u I u I u I u I u I u I u I 
Keratome depth (mm) 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.5 0.3 0.5 0.3 0.3 0.4 0.4 
00 0.2 1.8 2.0 2.5 1.8 3.1 2.3 2.9 2.3 3.0 0.2 0.5 1.9 4.8 3.0 1.6 
Control 0.1 1.8 1.0 4.6 1.2 2.8 1.9 2.5 1.8 1.9 0.2 1.1 , 0.1 3.8 ND ND 
Histamine 8.0 16.3 5.6 19.1 7.4 10.1 7.3 9.5 52.6 71.0 5.7 6.2 3.5 20.9 4.0 15.0 
AMP or Adenosine 24.0 25.8 19.3 23.3 35 11.4 27.2 32.1 74.5 83.3 7.7 9.0 19.9 38.4 12.9 13.1 
Epinephrine 59.6 30.8 68.6 19.4 149 14.5 14.4 10.3 58.3 37.8 35.0 4.0 ND ND 21.1 6.0 
a Asthmatic patient, epinephrine inhalation was used until 30 min prior taking the skin. 
UNINVOLVED INVOLVED 
cAMP p moles / mg protein 
FIG 3. Differential responses to histamine, AMP and epinephrine by 
the uninvolved and involved skin from psoriatic patients. The averages 
(± SE) for the epidermal cyclic AMP accumulation are computed from 
data in Table II. For detailed experimental condition c.f. Table II. 
consistently showed better response to epinephrine and weaker 
response to histamine. The response to AMP or adenosine by. 
the uninvolved and involved was about equal except for case 3 
and 7 where each uninvolved and involved skin showed better 
response respectively. This general tendency is summarized in 
Fig 3. The difference in the histamine response between the 
uninvolved and involved skin was analyzed by a paired Student 
t-test and was statistically significant (p < 0.01). The difference · 
in response to epinephrine is marked and significant: the in-
volved skin lost nearly 75% of it's responsiveness. The results 
are in accordance with our previous data [9]. To exclude the 
possibility that the cyclic AMP-leakage into medium during 
the incubation of psoriatic skin with epinephrine and theo-
phylline, thereby the involved psoriatic skin showed apparently 
lower response to epinephrine, we also measured the cyclic 
AMP levels in the incubation media in which psoriatic tissues 
had been incubated with epinephrine and theophylline for 7 
min. For this purpose, we purified cyclic AMP in the media by 
column chromatography as described in "Methods" in order to 
avoid the possible interference by substances in the media. The 
results clearly show that up to 7 min of the incubation period, 
the leakage of cyclic AMP in the medium is none or negligible. 
Table II also suggests that the basal cyclic AMP levels (00 
and controls) in the involved epidermis are higher than those 
in the uninvolved. Since these values are those after the pre-
incubation and do not represent an endogenous (steady state) 
cyclic AMP level, the significance of this difference awaits 
elucidation. The cyclic AMP level which has increased tran-
siently due to ischemia effect [19,22] after biopsy gradually 
declines during the pre-incubation period. 
Table III shows the effect of epinephrine at the transitional 
zone of a psoriatic plaque. Due to the limited area of the 
transitional zone, only the epinephrine response was investi-
gated. Clearly, the involved epidermis responded weakly as 
TABLE III. Effect of epinephrine at the transitional zone 
7 mm 7 mm 
"-Uninvolved~ Involved ......I 
A: Uninvolved transitional zone. B: Involved transitional zone. 
S kin was taken as a single sheet and each strip of 7 mm width from 
the boundary was used as the transitional zone. The arrow indicates 
clinical separation between the involved and uninvolved. The cyclic 
AMP value with no addition of epinephl'ine was 0.4-3.6 pmoles/ mg 
protein. Incubation period was for 7 min with 50 l-IM epinephl'ine and 5 
mM theophylline. 
Cyclic AMP pmoles/ mg protein 
Uninvolved Involved 
Case 
Uninvolved Involved 
Uninvolved Transitional Transitional Involved (A) (B) 
1 92.0 63.6 60.8 ND" 
2 82.4 78.7 36.1 17.7 
3 149 141 56.9 14.5 
8 ND 52.0 10.6 6.0 
a ND = not determined 
compared with the uninvolved epidermis, and the transitional 
responses were in-between. Thus, the uninvolved epidermis 
adjacent to psoriatic lesion responded less than the uninvolved 
but better than the lesional epidermis at the edge did. Also, the 
lesional epidermis at the border responded better than the 
involved skin (c.f. a diagram in Table III). 
DISCUSSION 
Our data show that histamine and adenosine (or AMP) cause 
cyclic AMP accumulation in psoriatic human skin (uninvolved 
and involved). Since these effects were highly potentiated by 
the addition of phosphodiesterase inhibitors, it seems they act 
on the adenylate cyclase as is the case in pig skin [15,17]. These 
histamine and AMP responses by human skin appears generally 
to be somewhat weaker than those of pig skin. Since we did not 
study the response of normal human epidermis, the question of 
whether this difference is due to a species difference or due to 
the disease remains unclear. 
The major purpose of this study was to see if different 
responses to the 3 adenylate cyclase stimulators occurred be-
tween uninvolved and involved skin. Variability in degrees of 
responsiveness between the patients was observed in the 8 cases 
(Table II) . The cause of this variability remains uncleal' at this 
time, but it is interesting to note that in case 4 (who had 
epinephrine inhalation 30 min before the biopsy), the epineph-
rine response was very weak and there was no difference in 
response between the uninvolved and involved epidermis. In 
this case, the previous exposure to the epinephrine may have 
induced refractoriness to the epinephrine response [23,24]. The 
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variability might also be in part explained by contamination of 
different dermal components. The thickness of the involved 
psoriatic epidermis is quite variable [25]. In most of our cases 
we could obtain whole layers of epidermis from the uninvolved 
area by a keratome with a 0 .3 mm setting, but this depth was 
sometimes not deep enough to get whole epidermis from the 
involved area. The thickness of t he skin is variable with the 
a ngle of the cutting blade, the pressure applied, and the speed 
of cutting [26]. 
In spite of the variability of responses from patient to patient, 
if we compare the responses in each case, the epinepluine 
response is markedly different from the histamine and AMP 
response, i.e. , the epinephrine response (and probably the PGE 
response [11,12]) was much higher in the involved epidermis. It 
should be noted that this tendency was the same even when we 
compare the effect of agents on skin cut so as to minimize the 
effect of different dermal components (case 5, 6). The physio-
logical significance of this apparent discrepancy between the 
receptor specific responses remains to be solved, however, these 
results suggest that the total catalytic activity of the psoriatic 
plaque might not be defective even though the epinephrine 
receptor system of adenylate cyclase is severely defective in the 
lesion. This is compatible with the results of Harkonen, Hopsu-
Hava, and Raij [5], who showed that the response of adenylate 
cyclase to sodium fluoride was similar in normal and psoriatic 
epidermis. 
As far as the epinephrine effect at the transitional zone is 
concerned, our data suggest that the zone does not represent 
the characteristics of the purely involved or purely uninvolved 
epidermis. It would be of interest to study the transition zone 
in a lesion known to be evolving or clearing. 
In summa1·y, these results indicate that the 4 known sites for 
activation of adenyl cyclase are affected in quite specific fashion 
when the normal-appearing skin become a psoriatic plaque. 
The plaque loses almost 75% of its responsiveness to epineph-
rine, loses about 50% of its responsiveness to PGE, is unchanged 
in response to AMP or adenosine, and gains 80% in responsive-
ness towru·d histamine. Although these changes are not known 
to be specific for psoriasis, they do make it unlikely that the 
unresponsiveness to epinephrine is due to a generalized inability 
of the cell membrane to make proper, functioning receptors. 
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